The last quote is really fantastic. The way our plan is going right now, we will have both in our hands.
As far as I know, no other ASX MedCann has both at a mature stage yet, if not at all?
From my brief research, AGH has patient acquisition, mainly due to their partnership with CannVaLate and by Dr Sud's estimates EOY we will be 2/3 of AGH's patients.
BOT, our other immediate large peer is on track for the latter, with their clinical trials. They have already completed one or two iirc.
Both boasted far above 200M MC at their peaks, I think AGH is still above 200M MC.
That's crazy, and thats just InCannex, nothing to do with the soon to be FCF+ Dental Biz too.
We have everything lined up, its incredibly ambitious but with the quality of the BOD and now with Dr Sud involved who else better qualified?
Most of our peers are focusing on either redundant areas and failing, cultivation and growth, or one of the two factors that Dr Sud has identified.
We are taking on both of those determinants, upside potential is insane from here. Only major risk is that the entire sector suddenly turns into negative sentiment overnight, which would likely not happen. We are the best ASX MedCann in theory, no doubt about it.
The key word here is theory, plenty of nay-sayers will hinge on that chance. Execution is all that matters, but with our BOD so far anyone who's been in IHL for a while now will know just how good the team is at executing. You know what the hardest part is? Patience. Waiting, letting the Board execute the plan which would make us have two gold mines in our hands. And of course, topping up when pullbacks and profit taking occurs.
GLTA
